Skip to main content
Terug
BDULF logo

Bangkok Dusit Medical Services Public Company Limited

Datakwaliteit: 100%
Overbought
BDULF
OTC Healthcare Medical - Care Facilities
€ 0,66
€ 0,00 (0,00%)
Marktkapitalisatie: 10,49B
Ook genoteerd als BDUUY OTC BDUUF OTC
Dagbereik
€ 0,66 € 0,66
52-Weeksbereik
€ 0,56 € 0,74
Volume
1.000
50D / 200D Gem.
€ 0,61 / € 0,63
Vorige Slotkoers
€ 0,66

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,7 0,3
P/B 0,1 2,9
ROE % 15,4 3,7
Net Margin % 14,2 3,8
Rev Growth 5Y % 10,6 10,0
D/E 0,2 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,00
€ 0,00 – € 0,00
 120 B 0
FY2026 € 0,00
€ 0,00 – € 0,00
 120 B 0

Belangrijkste Punten

Revenue grew 10,60% annually over 5 years — strong growth
ROE of 15,39% — decent returns on equity
Debt/Equity of 0,17 — conservative balance sheet
Generating 13,02B in free cash flow
P/E of 0,66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,31%

Groei

Revenue Growth (5Y)
10,60%
Revenue (1Y)3,29%
Earnings (1Y)-0,95%
FCF Growth (3Y)2,18%

Kwaliteit

Return on Equity
15,39%
ROIC11,22%
Net Margin14,21%
Op. Margin16,56%

Veiligheid

Debt / Equity
0,17
Current Ratio0,98
Interest Coverage51,78

Waardering

P/E Ratio
0,66
P/B Ratio0,10
EV/EBITDA1,17
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,29% Revenue Growth (3Y) 5,11%
Earnings Growth (1Y) -0,95% Earnings Growth (3Y) 4,96%
Revenue Growth (5Y) 10,60% Earnings Growth (5Y) 18,85%
Profitability
Revenue (TTM) 111,42B Net Income (TTM) 15,84B
ROE 15,39% ROA 10,03%
Gross Margin 34,91% Operating Margin 16,56%
Net Margin 14,21% Free Cash Flow (TTM) 13,02B
ROIC 11,22% FCF Growth (3Y) 2,18%
Safety
Debt / Equity 0,17 Current Ratio 0,98
Interest Coverage 51,78 Dividend Yield 0,04%
Valuation
P/E Ratio 0,66 P/B Ratio 0,10
P/S Ratio 0,09 PEG Ratio -19,43
EV/EBITDA 1,17 Dividend Yield 0,04%
Market Cap 10,49B Enterprise Value 21,64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 111,42B 107,87B 100,85B 91,93B 74,45B
Net Income 15,84B 15,99B 14,38B 12,61B 7,94B
EPS (Diluted) 1,00 1,01 0,90 0,79 0,50
Gross Profit 38,89B 39,80B 37,44B 33,60B 24,99B
Operating Income 18,45B 20,51B 18,94B 16,99B 11,23B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 157,83B 151,51B 143,60B 141,54B 128,45B
Total Liabilities 47,91B 47,59B 44,72B 47,83B 40,69B
Shareholders' Equity 105,81B 100,04B 95,44B 89,88B 83,85B
Total Debt 17,49B 18,36B 18,13B 23,59B 18,83B
Cash & Equivalents 6,34B 7,37B 7,79B 12,67B 10,93B
Current Assets 23,09B 23,66B 23,55B 27,80B 24,40B
Current Liabilities 23,61B 22,01B 18,43B 20,62B 15,86B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#113 of 827
63
Custom Contrarian Investing (David Dreman)
#593 of 670
6
Value Defensive Investing (Benjamin Graham)
#278 of 709
34

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026